Abstract. In this study, we examined the effect of Cd on the expression of vascular cell adhesion molecule-1 (VCAM-1) and its mechanisms in bEnd.3 cells. The treatment with Cd increased protein and mRNA expressions of VCAM-1 and increased the phosphorylations of p38, JNK, and ERK. The Cd-induced VCAM-1 expression was significantly suppressed by either a specific p38 mitogen-activated protein kinase (MAPK) inhibitor (SB202190) or a JNK inhibitor (SP600125), but not by an ERK inhibitor (U0126). These results suggest that Cd induces the expression of VCAM-1, at least in part, via p38 and JNK pathways in bEnd.3 cells.
It is well established that adhesion of leukocytes to the endothelium is one of the pathological processes that leads to a wide range of inflammatory diseases. Cell adhesion molecules are critical players in the regulation of adhesion of circulating leukocytes to endothelial cells and subsequent transmigration of leukocytes across the blood vessels, leading to inflammation. Among the endothelial cell adhesion molecules, intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) are known to play roles in mediating the firm adhesion of leukocytes to endothelial cells. Similar to ICAM-1, VCAM-1 acts not only as an adhesion molecule, but also acts as a signal transducer upon binding of leukocytes. In spite of their structural and functional similarity, considerable differences between ICAM-1 and VCAM-1 have been reported due to their distinct magnitudes and kinetics in their expressions in response to stimuli in various organs (1) .
Cadmium (Cd), a highly ubiquitous heavy metal, has been reported to be involved in endothelial dysfunctions through the adhesion-induced inflammatory response. We previously have demonstrated that Cd induces ICAM-1 expression possibly through p38 mitogenactivated protein kinase (MAPK) activation in bEnd.3 cells (2, 3) , suggesting that ICAM-1 expression may be associated with inflammatory injury in the blood brain barrier (BBB). In this study, we investigated the effect of Cd on the expression VCAM-1 and its underlying mechanism, especially focusing on MAPKs signaling pathways.
Mouse brain endothelium-derived bEnd.3 cells and human endothelium-derived EA.hy926 cells were grown in Dulbecco's modified Eagle's medium (DMEM; Gibco, Gaithersberg, MD, USA) supplemented with 10% fetal bovine serum. Cells were treated with CdCl 2 (dissolved in distilled water) (Sigma, St. Louis, MO, USA) in serumfree DMEM media at several concentrations for the indicated periods in the presence or absence of MAPKs inhibitors. Cell viability was determined by a 3-[4,5-dimethyl-triazolyl-2]2,5-diphenyl tetrazolium bromide (MTT) assay. Expressions of VCAM-1 protein were examined by immunocytochemistry using a polyclonal VCAM-1 antibody (1:500; Santa Cruz Biotechnology, Santa Cruz, CA, USA), and the levels were quantita-tively analyzed with confocal microscopy (Carl Zeiss, Oberkochen, Germany). VCAM-1 mRNA expressions were measured by RT-PCR using gene-specific primers for mouse VCAM-1 and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) as an internal control: VCAM-1: 5'-GGC TCG TAC ACC ATC CGC-3' (sense) and 5'-CGG CAT CCT GCA GCT GTG CCT-3' (antisense); GAPDH:
5'-CAA AGT TGT CAT GGA TGA CC-3' (sense) and 5'-CCA TGG AGA AGG CTG GG-3' (antisense). From the preliminary test for various PCR cycles and temperature, we determined the following optimal conditions: for VCAM-1, 30 cycles of denaturing at 95°C for 30 s, annealing at 57°C for 30 s, and extension at 72°C for 40 s; for GAPDH, 25 cycles of denaturing at 95°C for 30 s, annealing at 57°C for 20 s, and extension at 72°C for 40 s. The phosphorylations of MAPKs were measured by western blotting analysis using different primary MAPKs antibodies (Calbiochem, San Diego, CA, USA). All data were expressed as the mean ± S.E.M. from at least three different experiments. The comparisons were made with Student's t-tests. A P value of <0.05 was considered significant.
As shown in Fig. 1A , the treatment with 3 and 10 µM Cd for 4 h significantly elevated protein expressions of VCAM-1 by 447.1 ± 172.7% and 592.9 ± 166.2%, respectively, compared to the control (100 ± 107.8%). Up to the concentration of 10 µM, Cd did not show any cytotoxic effect (data not shown). When cells were treated with 10 µM Cd for the indicated periods, the expression level of VCAM-1 protein was significantly increased as early as 2 h (369.5 ± 61.4% of the control) with a peak at 4 h after Cd treatment (590.9 ± 119.7%) (Fig. 1B) . The level of VCAM-1 mRNA started to increase 1 h after the treatment with Cd, reaching a peak at 2 h (Fig. 1C) .
To investigate the involvement of MAPKs signaling in Cd-induced VCAM-1 expression, the effects of MAPKs inhibitors were examined. In bEnd.3 cells, 10 µM Cd-induced VCAM-1 protein and mRNA expressions were remarkably inhibited by either 20 µM SB202190 (p38 inhibitor) or 5 µM SP600125 (JNK inhibitor), but not by 20 µM U0126 (ERK inhibitor) (Fig. 2: A and C) . Similarly, the inhibitory effects of SB202190 and SP600125 on VCAM-1 expressions were also shown in Cd-treated EA.hy926 cells (Fig. 2B) . None of the three MAPK inhibitors showed any effect on the VCAM-1 expression in Cd non-treated cells (data not shown).
To examine whether 10 µM Cd affects the phosphorylation of MAPKs, immunoblot analyses were performed with antibodies. As shown in Fig. 3A , the phosphorylations of p38, JNK, and ERK MAPK were increased at 5 and 15 min after exposure to Cd, with subsequent decrease. The phosphorylation of p38 MAPK was increased again after 60 min of Cd treatment; this biphasic time-dependent response to Cd was significantly shown in all four separate experiments. The phosphorylations of p38, JNK, and ERK MAPK at 5-min exposure to Cd were inhibited in the presence of their specific inhibitors, respectively (Fig. 3B) . Although the JNK and ERK inhibitors seemed to slightly decrease the phosphorylation of p38, it was statistically not significant.
In the present study, we for the first time demonstrate that Cd significantly induces the expression of VCAM-1, at least partially, through p38 and JNK MAPK pathways in bEnd.3 cells.
Brain microvessel endothelial cells, a major component of the BBB, act as a barrier against the entry of blood-borne substances and leukocytes into the central nervous system under physiological conditions. In pathological conditions such as stroke and multiple sclerosis, BBB integrity can be disrupted by transmigrations of leukocytes, that are induced by activated adhesion molecules such as ICAM-1 and VCAM-1, across the cerebrovascular endothelium, leading to inflammation (4). Although VCAM-1 is structurally similar to ICAM-1, its regulation pattern and functions are different from ICAM-1. VCAM-1 is not expressed under baseline conditions, but is rapidly induced upon endothelial activation by various pathologic stimuli (5). In several diseases, such as encephalomyelitis and atherosclerosis, VCAM-1 has been demonstrated to play a more important pathogenic role than ICAM-1. Taken together, it is suggested that VCAM-1 should have attention as an important therapeutic target for inflammatory diseases (5, 6) .
Environmental pollutants including Cd exert pathological and toxicological effects on the brains of animals and humans (7, 8) . Chronic exposure to Cd (10 µg/ml) has been demonstrated to induce BBB dysfunction and increase BBB permeability in rats (8) . Indeed, ICAM-1 has been reported to increase in bEnd.3 cells, implicating its potential role in Cd-induced BBB endothelial dysfunction (2, 3) . Furthermore, the present study demonstrates that 3 -10 µM Cd increases the expression of the VCAM-1 at both the protein and mRNA levels in a dose-and time-dependent manner in bEnd.3 cells. Taken together, it is suggested that VCAM-1 expression as well as ICAM-1 expression may be associated with BBB dysfunction and further brain damage when exposed to Cd.
Although the signaling pathways of VCAM-1 expression in endothelial cells have been studied extensively, especially focusing on MAPKs, they remain unclear. Indeed, there are controversial reports concerning which MAPKs are relevant to VCAM-1 expression (9, 10), with a number of studies reporting that p38 and/or JNK signaling cascades are preferentially involved in the mechanism of VAM-1 expression in various cells including endothelial cells (11, 12) . Consistent with these results, this study showed that the phosphorylation of p38 and JNK seemed to be associated with VCAM-1 expression in bEnd.3 cells treated with Cd (Figs. 2 and  3) . Moreover, similar results were shown in human endothelial cells, EA.hy926 cells (Fig. 2B) . However, because EA.hy926 cells are not brain endothelial cells, further studies, therefore, must be performed using human brain endothelial cells in order to more conclusively demonstrate the relevance of p38 /JNK in VCAM-1 expression in human BBB endothelium. Interestingly, in our previous study, p38, but not JNK, was activated after more than 30 min of Cd treatment at lower concentration (2 µM) in bEnd.3 cells (3), mediating ICAM-1 expression. The inconsistency about the effect of Cd on JNK phosphorylation is likely due to the different concentrations and durations of Cd treatment. Nonetheless, from these results it is suggested that VCAM-1 and ICAM-1 seem to share a common signaling pathway of, at least, p38 MAPK in the process of Cd-induced BBB endothelial injury.
Generally, p38 and/or JNK pathways are primarily activated by various types of environmental stress including reactive oxygen species (ROS), whereas the ERK pathway is most commonly linked to the regulation of cell proliferation (13) . Indeed, p38-and JNKsignaling pathways are known to be strongly activated by ROS induced by metal ions such as Cd and Cu (14, 15) , suggesting ROS as an upstream signaling molecule of p38 and/ or JNK activation induced by metal ions.
In conclusion, it is suggested that an intervention targeting VCAM-1, in addition to ICAM-1, should be performed to prevent cerebrovascular lesions under Cd exposure.
